“the IDMC has not stopped the trial yet because of not going to meet the primary endpoint.”
That is an assumption on your part that you think you know what the DMC has said to the company. Also the DMC provides a recommendation. It is up to the company to do what they want with that recommendation.
My feeling is based on old thinking the PFS failed but if taking pseudo progression into account then PFS probably did not fail. The only way to know is adjudicate the scans with survival over the longer term. Like right now at the end of the trial.
News 
Market Data 
Discover 
